Abstract:Introduction The Src Family Kinases (SFKs) are key mediators in various oncogenic pathways and are commonly activated in many forms of cancer. Of the nine members of SFKs, increasing reports suggest aberrant activation of Lyn and Fyn in breast cancer. Bioinformatics analysis reveals that Lyn and Fyn expression are strongly associated with the claudin-low TNBC patient group. Due to the current lack of targeted therapy for the TNBC subtype, it becomes worthwhile to investigate the potential of Lyn and Fyn as novel therapeutic targets. While preclinical studies involving current SFK inhibitors were promising, subsequent clinical trials have shown limited clinical benefits. In this project, we developed a novel in-house SFK inhibitor (Drug X) that specifically targets Lyn and Fyn kinases. Material and methods Patient data analysis, Ligand-based computation, Proteome Profiler Array, in vivo mouse Pharmacokinetics and Pharmacodynamics studies, Bioinformatics analysis, Affymetrix Microarray, Secretome Analysis, Cell viability assays, Flow cytometry, Western blot, qPCR, Immunofluorescence, Transwell assays, 3D Matrigel Assays, and Tube-formation assay. Results and discussions Proteome Profiler Array results validated the ligand-based target prediction analyses of Drug X in vitro. Mouse studies show that Drug X is well-tolerated and exhibited significant tumour burden load reduction. Pharmacokinetics of Drug X was characterised. Overall, Drug X showed moderate systemic clearance, high volume of distribution and moderate oral bioavailability. Downstream functional studies were performed, and Drug X was found to induce apoptosis via the intrinsic pathway. Also, Drug X could down-regulate the mesenchymal properties of mesenchymal-like TNBC cell lines via the modulation of key EMT-related genes. Preliminary in vitro and in vivo rat aortic ring assay data also suggested that Drug X could harbour potent anti-angiogenic effects. Conclusion Based on in vitro and in vivo experiments, preliminary findings have supported that Drug X could potentially be a promising novel drug candidate for TNBC treatment and on-going efforts are being made to further elucidate the underlying mechanisms of Drug X in modulating the key oncogenic processes – namely from the angle of apoptosis, EMT and angiogenesis.

Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives As A New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer

From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives As Agents for the Treatment of Triple Negative Breast Cancer

3D-QSAR, molecular docking, and new compound design of pyrimidine derivatives as Src small molecule inhibitors

Design, Synthesis and Structure-Activity Relationship Studies of a Focused Library of Pyrimidine Moiety with Anti-Proliferative and Anti-Metastasis Activities in Triple Negative Breast Cancer.

Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold As Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies

Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase

Development of 2'-aminospiro [pyrano[3,2-c]quinoline]-3'-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation

Synthesis and mechanism of action of new purine derivatives against triple negative breast cancer

Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2h,4h)-dione Analogues: Development of Potent Eef2k Degraders Against Triple-Negative Breast Cancer.

PO-462 Investigating the Potential Anti-Cancer Properties of a Novel Src Family Kinase Inhibitor in Triple Negative Breast Cancer

Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2 H,4 H)-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer

Design, Synthesis and Biological Evaluation of Anilide (dicarboxylic Acid) Shikonin Esters As Antitumor Agents Through Targeting PI3K/Akt/mTOR Signaling Pathway

Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer

Synthesis and Biological Evaluation of Novel Ligustrazine-Chalcone Derivatives As Potential Anti-Triple Negative Breast Cancer Agents

Design, Synthesis and Antitumor Activity of Novel Thiophene- Triazine Derivatives Bearing Arylurea Unit As Potent PI3K/mTOR Inhibitorss.

Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment.

Design, Synthesis and Anti-Breast Cancer Evaluation of Biaryl Pyridine Analogues As Potent RSK Inhibitors

Design, synthesis and antitumor evaluation of 3-chloro-4 - (pyridin-2-ylmethoxy) aniline derivatives as BCR-ABL kinase

PH006, a Novel and Selective Src Kinase Inhibitor, Suppresses Human Breast Cancer Growth and Metastasis in Vitro and in Vivo

Synthesis and Anti-Tumor Activity Evaluation of 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide Derivatives with Phenyl Sulfonamide Groups As Potent RSK2 Inhibitors

Design, Synthesis, Antitumor Activity Evaluation, and Molecular Dynamics Simulation of Some 2-Aminopyrazine Derivatives